Tscan Therapeutics Inc (TCRX)
$8.48
Insights on Tscan Therapeutics Inc
Decreasing Revenue
Revenue is down for the last 2 quarters, 7.21M → 566.0K (in $), with an average decrease of 92.2% per quarter
Decreasing Net Profit
Netprofit is down for the last 2 quarters, -19.61M → -30.14M (in $), with an average decrease of 53.7% per quarter
Performance
- $8.24$9.13$8.48
2.83%
Downside
Day's Volatility :9.75%
Upside
7.12%
- $1.93$9.69$8.48
77.24%
Downside
52 Weeks Volatility :80.08%
Upside
12.49%
Returns
| Period | Tscan Therapeutics Inc | Index (Russel 2000) |
|---|---|---|
3 Months | 19.1% | 0.0% |
6 Months | 38.56% | 0.0% |
1 Year | 206.14% | 0.0% |
3 Years | -19.24% | -22.6% |
Highlights
Market Capitalization | 452.0M |
Book Value | $2.57 |
Earnings Per Share (EPS) | -0.75 |
Wall Street Target Price | 12.57 |
Profit Margin | 0.0% |
Operating Margin TTM | -5542.93% |
Return On Assets TTM | -30.79% |
Return On Equity TTM | -96.32% |
Revenue TTM | 14.8M |
Revenue Per Share TTM | 0.18 |
Quarterly Revenue Growth YOY | -91.7% |
Gross Profit TTM | -46.3M |
EBITDA | -97.0M |
Diluted Eps TTM | -0.75 |
Quarterly Earnings Growth YOY | 0.0 |
EPS Estimate Current Year | -1.21 |
EPS Estimate Next Year | -1.34 |
EPS Estimate Current Quarter | -0.26 |
EPS Estimate Next Quarter | -0.25 |
Analyst Recommendation
- Current
- 1M Ago
- 3M Ago
Analyst Forecast
What analysts predicted
Upside of 48.23%
Technicals Summary
Sell
Neutral
Buy
Tscan Therapeutics Inc is currently in a favorable trading position ( BUY ) according to technical analysis indicators.
Peers
| Company Name | 1 Month | 6 Month | 1 Year | 3 Years | 5 Years |
|---|---|---|---|---|---|
 Tscan Therapeutics Inc | -3.75% | 38.56% | 206.14% | -19.24% | -19.24% |
 Moderna, Inc. | 21.03% | 85.08% | 14.68% | -28.27% | 659.22% |
 Regeneron Pharmaceuticals, Inc. | 3.22% | 20.18% | 31.88% | 93.3% | 227.58% |
 Novo Nordisk A/s | 8.85% | 34.38% | 71.83% | 235.07% | 463.44% |
 Vertex Pharmaceuticals Incorporated | 16.81% | 34.1% | 40.6% | 123.97% | 174.53% |
| Company Name | P/E Ratio | P/B Ratio | PEG Ratio | EPS | ROE | ROA | Div Yield | BVPS |
|---|---|---|---|---|---|---|---|---|
Tscan Therapeutics Inc | NA | NA | NA | -1.21 | -0.96 | -0.31 | NA | 2.57 |
Moderna, Inc. | 24.73 | NA | 0.0 | -7.14 | -0.38 | -0.16 | NA | 33.47 |
Regeneron Pharmaceuticals, Inc. | 28.89 | 28.89 | 1.46 | 44.13 | 0.15 | 0.08 | NA | 250.15 |
Novo Nordisk A/s | 46.97 | 46.97 | 2.36 | 3.5 | 1.0 | 0.25 | 0.01 | 22.18 |
Vertex Pharmaceuticals Incorporated | 29.59 | 29.59 | 0.53 | 17.08 | 0.24 | 0.13 | NA | 71.8 |
| Company Name | Analyst View | Market Cap | 5 Years Return % | PE Ratio | Profit Margin |
|---|---|---|---|---|---|
Tscan Therapeutics Inc | Buy | $452.0M | -19.24% | NA | 0.0% |
Moderna, Inc. | Buy | $54.6B | 659.22% | 24.73 | -115.82% |
Regeneron Pharmaceuticals, Inc. | Buy | $108.0B | 227.58% | 28.89 | 29.45% |
Novo Nordisk A/s | Buy | $602.6B | 463.44% | 46.97 | 36.55% |
Vertex Pharmaceuticals Incorporated | Buy | $117.5B | 174.53% | 29.59 | 39.46% |
Institutional Holdings
EcoR1 Capital, LLC
9.46%Adage Capital Partners Gp LLC
7.38%Bvf Inc
5.66%Baker Bros Advisors LP
5.27%Propel Bio Management LLC
3.95%Vanguard Group Inc
3.42%
Company Information
harnessing novel t cell systems to extend the promise of immunotherapy
Organization | Tscan Therapeutics Inc |
Employees | 161 |
CEO | Dr. Gavin MacBeath Ph.D. |
Industry | Miscellaneous |
Discover More
A Spac I Acquisition Corp
$8.48
-0.82%
Keyarch Acquisition Corp
$8.48
-0.82%
Connexa Sports Technologies Inc
$8.48
-0.82%
Us Value Etf
$8.48
-0.82%
First Wave Biopharma Inc
$8.48
-0.82%
Global X Msci Next Emerging
$8.48
-0.82%
Fat Projects Acquisition Corp
$8.48
-0.82%
Capital Link Global Fintech
$8.48
-0.82%
Applied Uv Inc
$8.48
-0.82%